$95.24 5.6 6.3%
Last Trade - 21/04/21
| Market Cap | £42.70bn |
| Enterprise Value | £42.17bn |
| Revenue | £3.21bn |
| Position in Universe | 209th / 6852 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2,494 | 2,964 | 3,435 | 3,723 | 4,348 | 4,386 | 5,132 | 5,708 | +12.0% | ||
| +48.0 | +25.4 | +40.7 | +22.6 | +9.1 | +5.0 | +15.8 | +15.0 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products are categorized into three areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. It is developing products, such as the Edwards SAPIEN 3 Ultra System and Edwards SAPIEN XT transcatheter heart valve, among others. Its Transcatheter Heart Valve Therapy and Surgical Heart Valve Therapy products are manufactured in the United States, Singapore and Switzerland. Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.
| Last Annual | December 31st, 2020 |
| Last Interim | March 31st, 2021 |
| Incorporated | September 10, 1999 |
| Public Since | March 27, 2000 |
| No. of Shareholders: | 8,876 |
| No. of Employees: | 14,900 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector), |
| Exchange | New York Stock Exchange |
| Shares in Issue | 624,518,873 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | 1 Edwards Way, IRVINE, 92614-5688, United States |
| Web | https://www.edwards.com |
| Phone | +1 949 2502500 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 21/04/21, shares in Edwards Lifesciences are trading at $95.24, giving the company a market capitalisation of £42.70bn. This share price information is delayed by 15 minutes.
Shares in Edwards Lifesciences are currently trading at $95.24 and the price has moved by 32.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Edwards Lifesciences price has moved by -10.46% over the past year.
Of the analysts with advisory recommendations for Edwards Lifesciences, there are there are currently 7 "buy" , 10 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Edwards Lifesciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Edwards Lifesciences is scheduled to issue upcoming financial results on the following dates:
Edwards Lifesciences does not currently pay a dividend.
Edwards Lifesciences does not currently pay a dividend.
Edwards Lifesciences does not currently pay a dividend.
To buy shares in Edwards Lifesciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Edwards Lifesciences are currently trading at $95.24, giving the company a market capitalisation of £42.70bn.
Here are the trading details for Edwards Lifesciences:
Based on an overall assessment of its quality, value and momentum, Edwards Lifesciences is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Edwards Lifesciences are currently priced at $95.24. At that level they are trading at 2.79% discount to the analyst consensus target price of 0.00.
Analysts covering Edwards Lifesciences currently have a consensus Earnings Per Share (EPS) forecast of 2.177 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Edwards Lifesciences. Over the past six months, the relative strength of its shares against the market has been -2.58%. At the current price of $95.24, shares in Edwards Lifesciences are trading at 15.65% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Edwards Lifesciences PE ratio based on its reported earnings over the past 12 months is 54.04. The shares are currently trading at $95.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Edwards Lifesciences's management team is headed by:
Here are the top five shareholders of Edwards Lifesciences based on the size of their shareholding:
